Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07299344
Starting soon Observational

A Model for Continuous Care of Fragile Patients

NCT07299344 · tracked via the Priya Life Science Italy tracker
Sponsor
Azienda Sanitaria Locale CN2 Alba-Bra
Phase
Observational
Started
2025-12
Last updated
2025-12-23

Condition(s) studied

Neurological DisordersOrthopedic DisordersFunctional DeclineFragile and More Vulnerable

Investigational drug(s) / intervention(s)

Telemedicine-Based Functional Monitoring

Telemedicine-Based Functional Monitoring: This intervention provides structured functional monitoring of medically fragile patients with neurological and/or orthopedic conditions using telemedicine. Patients undergo MMSE, Rankin Scale, Barthel Index, TUG, GPCog, and SF-36 assessments at discharge and during follow-up at 3, 6, and 12 months. Patient and caregiver satisfaction with remote monitoring is also evaluated. All remote assessments are performed via the TESI eViSus BioCare® system on mobile devices, allowing early detection of functional decline and supporting proactive patient management.

Study summary

This observational study aims to monitor functional status and identify potential declines in the functioning of medically fragile patients with neurological and/or orthopedic conditions, representing an added value for ensuring appropriate patient management. This approach improves system efficiency and supports a proactive strategy that promotes the appropriate use of resources.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: * Adult medically fragile patients with one of the following neurological conditions: mild-to-moderate stroke (Rankin ≤ 3), Multiple Sclerosis (EDSS ≤ 6.5), Parkinson's disease or parkinsonisms, neuromuscular diseases; or orthopedic conditions: femur, pelvis, or humerus fracture. * Able to walk independently, with or without assistive devices. * Adequate cognitive function (MMSE ≥ 24). * Patient or caregiver owns and can use a mobile device with internet/data connection. * Presence of a cognitively capable, cooperative caregiver willing to participate in the study. Exclusion criteria: * Patients with severe neurological or orthopedic conditions who cannot walk independently, even with assistive devices. * Patients with moderate or severe cognitive impairment (MMSE \< 24). * Patients with Barthel Index \> 60. * Patients or caregivers unable to use a mobile device or without internet/data connection. * Patients without a cooperative, cognitively capable caregiver.

Primary outcome measure(s)

  • Concordance Between In-Person and Telemedicine Assessments of Functional and Cognitive Performance — 5-10 days after discharge
    Percentage of patients for whom the Timed Up and Go (TUG) test differs by less than 3.5 seconds and the GPCog test differs by less than 3 points between in-person and telemedicine assessments.

Trial sites (1)

FacilityCityRegionStatus
Azienda Sanitaria Locale CN2 Alba-Bra, Ospedale Michele e Pietro Ferrero Verduno CN

More Azienda Sanitaria Locale CN2 Alba-Bra trials in Italy

Longitudinal Randomized Controlled Study on the Effectiveness of Nutritional Education During Uncomplicated Pregnancy Active, not recruiting
Breast Density Impact on Mammographic Screening for Breast Cancer Diagnosis Recruiting

Other trials for the same condition

Cognitive Recovery Via Sensor-based Robotic Upper Limb Rehabilitation in Neurological Disorders Recruiting
Product Surveillance Registry Recruiting
A Muscle-brain Interplay Study in Neurological Disorders Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07299344 on ClinicalTrials.gov ↗ ← All trials in Italy